Testing RSLV-132 for Sjögren's disease in women
Part of Immune system & allergy clinical trials.
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman diagnosed with Sjögren's disease in the last 30 years.
- You have a positive blood test for anti-Ro/SSA antibodies.
- You have at least a moderate level of Sjögren's symptoms, especially fatigue, based on a standard questionnaire.
- You agree to use highly effective birth control if you could become pregnant, or you are not able to have children.
- You have not had major changes to your Sjögren's medications in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called ESG206, which targets a protein on immune cells, to see if it can safely reduce symptoms of primary Sjögren's syndrome. It is for people whose Sjögren's is not caused by another disease and who have active symptoms.
This trial tests an experimental drug, IMVT-1402, in adults with primary Sjogren's disease who have moderate to severe symptoms. The goal is to see if it can reduce disease activity safely.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
This trial tests an experimental drug called R-2487 for people with Sjogren's syndrome. It looks at safety and how well the drug works, and may offer a new treatment option.
This study tests an investigational drug called ICP-488 for people with primary Sjögren's syndrome (the main form, not caused by other conditions). The goal is to see if the drug can help control symptoms better than a placebo. Participants must have active disease and stable treatment.
This study tests a new drug called CM336 for people with primary Sjögren's syndrome (an autoimmune disease affecting salivary and tear glands). The drug is designed to help reduce disease activity in patients who haven't responded well to previous treatments.
Hear when a new Primary Sjögren Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.